immunology

READDI, Not Reactive

For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs, or vaccines were readily available. The Rapidly Emerging Antiviral Drug Development Initiative (READDI) — founded by researchers at UNC and the Structural Genomics Consortium — is not only finding solutions to the COVID-19 pandemic, but also drugs and therapeutics for future viral outbreaks.

Nilu Goonetilleke

Nilu Goonetilleke is an assistant professor in the Department of Microbiology and Immunology within the UNC School of Medicine. She studies the immune cell response to several major human infections, like HIV, and develops strategies to limit the causes and spread of disease.

Expecting the Unexpected

After Myron Cohen watched the first patient at UNC Hospitals die from AIDS in 1982, he knew it was a disease to be reckoned with. He spent the next 40 years helping to recruit the most promising infectious disease experts from across the nation to build a program that’s become a leader in HIV. Today, UNC excels in understanding all aspects of HIV, from prevention to a potential cure — expertise that is now being used to tackle COVID-19.